Phase 3 Cardiomyopathy Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been formally diagnosed with ATTR amyloidosis that has affected the heart (a condition where abnormal proteins build up in the heart muscle)
• People who have a medical history of heart failure
• People whose heart failure symptoms are well-controlled and whose condition has been stable in the 28 days before starting the study treatment
• People whose blood test result for a marker called NT-proBNP (which measures heart failure severity) falls between 600 pg/mL and 10,000 pg/mL at screening

Who may not be able to join:

• People with the most severe stage of heart failure (known as NYHA Class IV), meaning they have symptoms even at rest
• People who are confined to a wheelchair or bed due to nerve-related disability
• People who have hepatitis B, hepatitis C, or HIV infection
• People who have had an active cancer diagnosis within the 3 years before screening
• People who have taken certain RNA-based medications (patisiran, inotersen, or eplontersen) within the 12 months before dosing, or who have ever taken vutrisiran
• People who started taking tafamidis or acoramidis within 56 days before the study dosing date
• People whose kidneys are not functioning well enough, based on a specific blood test result falling below a set threshold (confirm with trial site)
• People with a history of liver disease
• People with blood pressure that is not well controlled
• People who are unable or unwilling to take vitamin A supplements for the entire duration of the study

Important: Always verify eligibility with the trial site directly before applying.